Total Payments
$15,775
2024 Payments
$45.17
Companies
9
Transactions
52
Medicare Patients
24,024
Medicare Billing
$19.3M
Payment Breakdown by Category
Other$14,559 (92.3%)
Food & Beverage$1,216 (7.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $8,315 | 1 | 52.7% |
| Current or prospective ownership or investment interest | $6,244 | 6 | 39.6% |
| Food and Beverage | $1,216 | 39 | 7.7% |
| Unspecified | $0 | 6 | 0.0% |
Payments by Type
General
$15,775
46 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $14,559 | 13 | $0 (2022) |
| Genentech USA, Inc. | $508.91 | 16 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $270.29 | 9 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $199.93 | 6 | $0 (2021) |
| Allergan, Inc. | $138.41 | 2 | $0 (2021) |
| Notal Vision, Inc. | $45.17 | 3 | $0 (2024) |
| Mallinckrodt LLC | $19.95 | 1 | $0 (2017) |
| Alimera Sciences, Inc. | $18.27 | 1 | $0 (2019) |
| EyePoint Pharmaceuticals US, Inc. | $15.30 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45.17 | 3 | Notal Vision, Inc. ($45.17) |
| 2022 | $10,636 | 4 | US Retina LLC ($10,636) |
| 2021 | $2,422 | 10 | US Retina LLC ($2,253) |
| 2020 | $830.60 | 7 | US Retina LLC ($722.28) |
| 2019 | $1,563 | 16 | US Retina LLC ($947.50) |
| 2018 | $120.65 | 2 | Allergan Inc. ($120.65) |
| 2017 | $157.84 | 10 | Genentech USA, Inc. ($96.11) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/11/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Ophthalmology | ||||||
| 03/14/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Ophthalmology | ||||||
| 02/08/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Ophthalmology | ||||||
| 08/09/2022 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $8,314.50 | General |
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $2,018.55 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $303.00 | General |
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 05/27/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/19/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Ophthalmology | ||||||
| 05/14/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,956.30 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $296.72 | General |
| 05/06/2021 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/15/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Ophthalmology | ||||||
| 04/02/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: RETINA | ||||||
| 03/30/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $58.47 | General |
| Category: Ophthalmology | ||||||
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 11/20/2020 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $722.28 | General |
| 03/12/2020 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/05/2020 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Ophthalmology | ||||||
| 01/23/2020 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 01/09/2020 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Ophthalmology | ||||||
| 2020 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/19/2019 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 5,690 | 40,817 | $17.0M | $4.4M |
| 2022 | 19 | 5,841 | 20,801 | $12.9M | $4.9M |
| 2021 | 20 | 6,427 | 20,093 | $9.7M | $5.0M |
| 2020 | 15 | 6,066 | 21,388 | $10.3M | $5.1M |
Total Patients
24,024
Total Services
103,099
Medicare Billing
$19.3M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 441 | 4,180 | $10.0M | $2.9M | 28.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 115 | 25,440 | $2.5M | $735,906 | 28.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 624 | 2,452 | $2.0M | $222,379 | 11.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 72 | 961 | $711,140 | $175,190 | 24.6% |
| 92134 | Imaging of retina | Office | 2023 | 1,465 | 3,555 | $391,050 | $99,758 | 25.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 910 | 1,146 | $389,640 | $96,590 | 24.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 589 | 1,187 | $284,880 | $76,339 | 26.8% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 20 | 205 | $236,800 | $44,553 | 18.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 260 | 260 | $104,000 | $25,040 | 24.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 771 | 886 | $132,900 | $15,928 | 12.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 63 | 157 | $62,800 | $9,983 | 15.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 78 | 79 | $31,600 | $8,090 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 111 | $27,750 | $7,504 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $25,500 | $5,912 | 23.2% |
| 92250 | Photography of the retina | Office | 2023 | 75 | 77 | $8,790 | $2,050 | 23.3% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 33 | 38 | $6,183 | $1,167 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 13 | $4,550 | $989.02 | 21.7% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 19 | 19 | $950.00 | $234.08 | 24.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 452 | 4,840 | $8.0M | $3.5M | 43.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 125 | 3,019 | $1.7M | $680,716 | 39.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 655 | 2,879 | $1.6M | $264,449 | 16.0% |
| 92134 | Imaging of retina | Office | 2022 | 1,499 | 3,961 | $361,940 | $115,547 | 31.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 942 | 1,240 | $348,800 | $109,515 | 31.4% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 650 | 1,174 | $237,120 | $72,737 | 30.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 18 | 1,920 | $192,000 | $57,295 | 29.8% |
About Dr. John Niffenegger, MD
Dr. John Niffenegger, MD is a Ophthalmology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518910280.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Niffenegger, MD has received a total of $15,775 in payments from pharmaceutical and medical device companies, with $45.17 received in 2024. These payments were reported across 52 transactions from 9 companies. The most common payment nature is "Acquisitions" ($8,315).
As a Medicare-enrolled provider, Niffenegger has provided services to 24,024 Medicare beneficiaries, totaling 103,099 services with total Medicare billing of $19.3M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Sarasota, FL
- Active Since 05/17/2006
- Last Updated 07/14/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1518910280
Products in Payments
- Lucentis (Biological) $505.91
- EYLEA (Biological) $228.51
- OZURDEX (Drug) $138.41
- BEOVU (Drug) $107.06
- Foresee Home (Device) $45.17
- EYLEA AFLIBERCEPT INJECTION (Biological) $41.78
- ACTHAR (Biological) $19.95
- Iluvien (Drug) $18.27
- YUTIQ (Drug) $15.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Sarasota
Dr. Daniel Kiernan, Md, MD
Ophthalmology — Payments: $1.9M
Ophthalmology $1.9M
Dr. Jody Abrams, M.d, M.D
Ophthalmology — Payments: $364,132
Ophthalmology $364,132
Keye Wong, M.d, M.D
Ophthalmology — Payments: $29,735
Ophthalmology $29,735
Dr. Marc Levy, Md, MD
Ophthalmology — Payments: $18,348
Ophthalmology $18,348
Tanuj Banker, M.d, M.D
Ophthalmology — Payments: $16,580
Ophthalmology $16,580
Melvin Chen, Md, MD
Ophthalmology — Payments: $4,621
Ophthalmology $4,621